Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul 10;39(20):2227-2231.
doi: 10.1200/JCO.20.03681. Epub 2021 Mar 26.

Rethinking Success in Pediatric Oncology: Beyond 5-Year Survival

AnnaLynn M Williams  1 , Qi Liu  2 , Nickhill Bhakta  1   3 , Kevin R Krull  1   4 , Melissa M Hudson  1   5 , Leslie L Robison  1 , Yutaka Yasui  1
Affiliations

Rethinking Success in Pediatric Oncology: Beyond 5-Year Survival

AnnaLynn M Williams et al. J Clin Oncol. .

Erratum in

  • Erratum.
    [No authors listed] [No authors listed] J Clin Oncol. 2022 Jul 10;40(20):2283. doi: 10.1200/JCO.22.01230. J Clin Oncol. 2022. PMID: 35793562 Free PMC article. No abstract available.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Kevin R. KrullPatents, Royalties, Other Intellectual Property: Royalties from Wolters Kluwer Melissa M. HudsonConsulting or Advisory Role: Oncology Research Information Exchange Network, Princess Máxima CenterNo other potential conflicts of interest were reported.

Figures

FIG 1.
FIG 1.
(A) Estimated numbers and proportions of excess deaths among childhood and adolescent cancer cases diagnosed at 0-19 years of age in the United States between 1975 and 2016, according to years from diagnosis by diagnosis, sex, and race (≤ 5.0 years after diagnosis [majority of excess deaths would be related to progressive disease, infection, or acute toxicity]; 5.0-9.9 years [excess deaths would reflect a mixture of recurrence or progressive disease plus deaths associated with treatment exposures]; ≥ 10.0 years post diagnosis [majority of excess deaths would be related to treatment exposures, with few from recurrence or progressive disease]); (B) estimated numbers of excess deaths among all childhood and adolescent cancer diagnosed at 0-19 years of age in the United States between 1975 and 2016, according to calendar year of death and years from diagnosis; (C) estimated numbers of excess deaths; and (D) absolute excess deaths per 1,000 patients or survivors at risk among childhood and adolescent patients with ALL, CNS malignancy, and HL, diagnosed at 0-19 years of age in the United States between 1975 and 2016, according to calendar year of death and years from diagnosis. ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; ES, Ewing sarcoma; GCT, germ cell tumor; HL, Hodgkin lymphoma; Liver, liver carcinomas; NBL, neuroblastoma; NHL, non-Hodgkin lymphoma; OS, osteosarcoma; RB, retinoblastoma; Renal, renal carcinomas; Rhabdo, rhabdomyosarcoma; STS, soft-tissue sarcoma.
See this image and copyright information in PMC

References

    1. Howlader NNA, Krapcho M, Miller D, et al., editors. SEER Cancer Statistics Review. Bethesda, MD: National Cancer Institute; 1975-2017. https://seer.cancer.gov/csr/1975_2017/ , based on November 2019 SEER data submission, posted to the SEER web site, April 2020.
    1. Smith MA, Altekruse SF, Adamson PC, et al. Declining childhood and adolescent cancer mortality Cancer 1202497–25062014 - PMC - PubMed
    1. Adamson PC.Improving the outcome for children with cancer: Development of targeted new agents CA Cancer J Clin 65212–2202015 - PMC - PubMed
    1. Wedekind MF, Denton NL, Chen CY, et al. Pediatric cancer immunotherapy: Opportunities and challenges Paediatr Drugs 20395–4082018 - PMC - PubMed
    1. Bhakta N, Liu Q, Ness KK, et al. The cumulative burden of surviving childhood cancer: An initial report from the St Jude Lifetime Cohort Study (SJLIFE) Lancet 3902569–25822017 - PMC - PubMed

Publication types